ZLN-005

Research use only, not for human use.

A novel small molecule PGC-1α transcriptional activator.

A novel small molecule PGC-1α transcriptional activator; increases expression of the PGC-1α gene and downstream genes by activation of AMP-activated protein kinase, and improves glucose uptake and fatty acid oxidation without obvious cytotoxicity in L6 myotubes; produces antihyperglycemia and antihyperlipidemia effects and increases insulin sensitivity in db/db mice.Diabetes Preclinical.

Western Blot Analysis Cell Line:L6 myotubes Concentration:2.5, 5, 10, 20 μM Incubation Time:24 hours Result:Dose-dependent activation of AMPK.

Animal Model:Eight-week-old db/db mice Dosage:15 mg/kg Administration:Oral administration; per day for 4 weeks Result:Random blood glucose and fasting blood glucose levels decreased significantly over 4 weeks compared with lean mice.

ZLN 005 | ZLN005

Nuclear Receptor/Transcription Factor

PGC-1α

PGC-1α

Metabolic Disease

Diabetes

49671-76-3

250.3382

C17H18N2

>98% (HPLC)

DMSO: ≥ 47 mg/mL

CC(C1=CC=C(C2=NC3=CC=CC=C3N2)C=C1)(C)C

1H-Benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-

(-20℃)

With Ice Pack

≥ 2 years